U.S. markets closed

Sino Biopharmaceutical Limited (SMZ1.F)

Frankfurt - Frankfurt Precio retrasado. Moneda en EUR.
Añadir a la lista de seguimiento
0.3202-0.0017 (-0.53%)
Al cierre: 06:23PM CEST

Sino Biopharmaceutical Limited

Unit 09, Office Tower
41st Floor, Room 4109 Convention Plaza 1 Harbour Road
Wan Chai
Hong Kong
852 2802 9886
https://www.sinobiopharm.com

Sector(es)Healthcare
IndustriaBiotechnology
Empleados a tiempo completo25,806

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Ms. Y. Y. TseExecutive Chairwoman of the Board6.52MN/D1992
Mr. Eric S. Y. TseCEO & Executive Director6.52MN/D1996
Mr. Ping TseFounder & Senior Executive Vice Chairman6.5MN/D1952
Ms. Cheung Ling ChengExecutive Vice Chairwoman of the Board5.66MN/D1964
Mr. Zhoushan TianExecutive Director250.52kN/D1964
Mr. Hsin TseSenior VP & Executive Director841.89kN/D1970
Ms. Chun Ling LiChief Financial OfficerN/DN/D1972
Mr. Song JinVice President of Public Affairs, Medicines Policies & ESGN/DN/D1976
Mr. Sean ChenChief Strategy OfficerN/DN/D1978
Orphanides GeorgeChief Scientific Advisor of invoXN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji; cardio-cerebral vascular medicines, such as irbesartan and hydrochlorothiazide tablets under the brand Yilunping and beraprost sodium tablets under the brand Kaina; and biosimilar medicines comprising adalimumab solution for injection under the brand Taibowei. In addition, the company develops oncology drugs, include benmelstobart, D-1553, TQ-B3139, and TQ-B3101; liver disease drugs, such as Lanifibranor and TQA2225/AP025; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.

Gestión corporativa

La calificación ISS Governance QuickScore de Sino Biopharmaceutical Limited a partir del 1 de junio de 2024 es 6. Las puntuaciones principales son Auditoría: 4; Junta: 1; Derechos del accionista: 7; Compensación: 9.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.